Names | |
---|---|
IUPAC name
(3Z,6Z)-3-Benzylidene-6-{[5-(2-methyl-2-propanyl)-1H-imidazol-4-yl]methylene}-2,5-piperazinedione
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEBI | |
ChemSpider | |
KEGG | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C19H20N4O2 | |
Molar mass | 336.395 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Plinabulin (provisional name BPI-2358, formerly NPI-2358) is a small molecule under development by BeyondSpring Pharmaceuticals, and has completed a world-wide Phase 3 clinical trial for non-small cell lung cancer. [1] Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia [2] and for anti-cancer effects in combination with immune checkpoint inhibitors [3] [4] and in KRAS mutated tumors. [5]
Plinabulin blocks the polymerization of tubulin in a unique manner, resulting in multi-factorial effects including an enhanced immune-oncology response, [6] [7] [8] activation of the JNK pathway [9] and disruption of the tumor blood supply.
Names | |
---|---|
IUPAC name
(3Z,6Z)-3-Benzylidene-6-{[5-(2-methyl-2-propanyl)-1H-imidazol-4-yl]methylene}-2,5-piperazinedione
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEBI | |
ChemSpider | |
KEGG | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C19H20N4O2 | |
Molar mass | 336.395 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Plinabulin (provisional name BPI-2358, formerly NPI-2358) is a small molecule under development by BeyondSpring Pharmaceuticals, and has completed a world-wide Phase 3 clinical trial for non-small cell lung cancer. [1] Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia [2] and for anti-cancer effects in combination with immune checkpoint inhibitors [3] [4] and in KRAS mutated tumors. [5]
Plinabulin blocks the polymerization of tubulin in a unique manner, resulting in multi-factorial effects including an enhanced immune-oncology response, [6] [7] [8] activation of the JNK pathway [9] and disruption of the tumor blood supply.